ClinicalTrials.gg
CompletedNCT00912743Updated Nov 9, 2016Results posted

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

A Phase 2 interventional study of olaparib in Colorectal Cancer, sponsored by AstraZeneca. Completed at 8 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2016-11-09.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Colorectal Neoplasms by AstraZeneca — 2 open to participants now, 8 under way, none of them phase 3. Colorectal Neoplasms · AstraZeneca.

Enrollment
21st of 28
33 · median 69
Started
2009
the only one that year
Phase 2
12 of 29
1 open now
Registered
12th of 29
by date

Among the 29 studies in Colorectal Neoplasms by AstraZeneca, this one is the 21st largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2009, is one of 12 in phase 2, and was the 12th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

2 of the 29 studies in Colorectal Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Colorectal Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This study is being carried out to see if the new drug, olaparib (AZD2281), can effectively and safely treat advanced large bowel cancer. The primary goal of this clinical trial is to determine whether olaparib will have a beneficial effect on the patient's cancer by causing a response and increasing the time it takes for the cancer to progress.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal cancer
  • Olaparib
  • MSI status
  • Stage IV
  • Measurable Colorectal Cancer
  • Stratified by MSI Status
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients will have measurable disseminated colorectal cancer that is incurable by surgery
  • Patients will have had tumor progression following standard combination front-line or chemotherapy.
  • CRC patients who have or recurrent disease within six months after completing or neoadjuvant chemotherapy

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with PARP inhibitors, including olaparib.
  • Patients with symptomatic, uncontrolled .
  • Patients receiving any chemotherapy, radiotherapy (except for palliative reasons), within 4 weeks from the last dose prior to study entry (or a longer period depending on the defined characteristics of the agents used).
  • Patients who are unable to swallow orally administered medication.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    1

    MSI - H arm

    Drug: olaparib

Interventions

06

What researchers measure

Primary outcomes

  1. Tumour Response

    Tumour response is the number of patients who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1)

    Time frame: From baseline, i.e. up to 28 days before first study drug dose, and then every 2 cycles (8 weeks) up to objective disease progression by RECIST, assessed up to 35 months

Secondary outcomes

  1. Progression Free Survival

    Progression free survival is defined as the duration from first dose till objective progression or death. In absence of progression or death, the time is calculated from first dose till last evaluable scanning visit.

    Time frame: From baseline, i.e. up to 28 days before first study drug dose, and then every 2 cycles (8 weeks) up to objective disease progression by RECIST, assessed up to 35 months

  2. Overall Survival

    Overall survival is defined as the duration from first dose till death from any cause. In absence of death, the time is calculated from first dose till the date subject last known to be alive

    Time frame: Survival follow-up from first dose till death of the patient or till end of study in absence of death, assessed up to 35 months

07

Results

Posted Nov 9, 2016

Participant flow

Target accrual: 54 subjects. MSI-H group: 15; non-MSI-H group: 39. Pre-planned interim analysis of the non-MSI-H cohort, after 17 patients, stopped recruitment into that cohort. Recruitment to the MSI-H cohort continued.

Participant flow — Overall Study
MilestoneMSI-HNon-MSI-H
Started1320
Completed00
Not completed1320
Withdrew: Adverse event31
Withdrew: Lack of efficacy918
Withdrew: Toxicity01
Withdrew: End of treatment form was not collected10

Outcome measures

PrimaryTumour Response

Tumour response is the number of patients who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1)

Time frame:
From baseline, i.e. up to 28 days before first study drug dose, and then every 2 cycles (8 weeks) up to objective disease progression by RECIST, assessed up to 35 months
Reported as:
Number · Percentage of Participants
Tumour Response
Percentage of ParticipantsMSI-HNon-MSI-H
Tumour Response0 (0 to 25)0 (0 to 17)
SecondaryProgression Free Survival

Progression free survival is defined as the duration from first dose till objective progression or death. In absence of progression or death, the time is calculated from first dose till last evaluable scanning visit.

Time frame:
From baseline, i.e. up to 28 days before first study drug dose, and then every 2 cycles (8 weeks) up to objective disease progression by RECIST, assessed up to 35 months
Reported as:
Median · days
Progression Free Survival
daysMSI-HNon-MSI-H
Progression Free Survival61 (52 to 360)55 (49 to 56)
SecondaryOverall Survival

Overall survival is defined as the duration from first dose till death from any cause. In absence of death, the time is calculated from first dose till the date subject last known to be alive

Time frame:
Survival follow-up from first dose till death of the patient or till end of study in absence of death, assessed up to 35 months
Reported as:
Median · days
Overall Survival
daysMSI-HNon-MSI-H
Overall Survival248 (121 to 554)290.5 (157 to 429)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MSI-H—6/13 (46.2%)12/13 (92.3%)
Non-MSI-H—3/20 (15%)20/20 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventMSI-HNon-MSI-H
Small intestinal obstructionGastrointestinal disorders2/130/20
HydronephrosisRenal and urinary disorders2/130/20
AnaemiaBlood and lymphatic system disorders1/130/20
Nodal rhythmCardiac disorders1/130/20
Abdominal painGastrointestinal disorders1/130/20
AscitesGastrointestinal disorders1/130/20
Gastrointestinal haemorrhageGastrointestinal disorders1/130/20
Intestinal obstructionGastrointestinal disorders1/130/20
Mucosal inflammationGeneral disorders1/130/20
Oedema peripheralGeneral disorders1/130/20
Most frequent other events
Showing 10 of 49
Most frequent other events
EventMSI-HNon-MSI-H
NauseaGastrointestinal disorders8/1315/20
AnaemiaBlood and lymphatic system disorders6/137/20
VomitingGastrointestinal disorders6/139/20
FatigueGeneral disorders5/138/20
ConstipationGastrointestinal disorders5/133/20
DiarrhoeaGastrointestinal disorders2/135/20
AnorexiaMetabolism and nutrition disorders3/135/20
Abdominal painGastrointestinal disorders3/134/20
DizzinessNervous system disorders3/131/20
RashSkin and subcutaneous tissue disorders3/133/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)MSI-HNon-MSI-HTotal
Mean51.77 ± 9.3761.80 ± 11.4657.85 ± 11.65
Sex: Female, Male
Sex: Female, Male(Participants)MSI-HNon-MSI-HTotal
Female6915
Male71118
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MSI-HNon-MSI-HTotal
White101929
Black or African American101
Asian101
Other112
08

Study locations

8 sites
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Palm Springs, California, United States
  • Research Site
    Aurora, Colorado, United States
  • Research Site
    Newark, Delaware, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Nashville, Tennessee, United States
  • Research Site
    Seattle, Washington, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 4 years 8 months after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2009
First posted
Jun 3, 2009
Start
May 2009
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Results delay requested
May 20, 2013
Results first posted
Nov 9, 2016
Last update
Nov 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00912743
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 3, 2009
Start date
May 2009
Primary completion
Mar 2012
Completion
Mar 2012
Results posted
Nov 9, 2016
Last update
Nov 9, 2016

Study contacts

Lawrence P Leichman, MD
principal investigator · Aptium Oncology Gastrointestinal Cancer Consortium
Bert H O'Neil, MD
principal investigator · Aptium Oncology Gastrointestinal Cancer Consortium
Jane Robertson, BSc, MBCHB, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion